SCHEMBL13290485

SCHEMBL13290485

CN(C)[C@H]1CC[C@H](C(=O)Nc2c(C(=O)Nc3ccc(Cl)cn3)oc3ccc(F)nc23)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ GSK3B P49841 8/20 0.41
▸ DYRK1A Q13627 8/20 0.41
▸ F10 P00742 4/20 0.41
▸ WNT1 P04628 3/20 0.41
▸ DEGS1 O15121 1/20 0.39
▸ BRD4 O60885 1/20 0.38
▸ TP53 P04637 2/20 0.38
▸ TSHR P16473 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ POLB P06746 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ PTBP1 P26599 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13290961 0.92 SMN1; SMN2 (0.42) SMN1; SMN2F10DEGS1BRD4TP53
SCHEMBL2947653 0.92 SMN1; SMN2 (0.43) SMN1; SMN2GSK3BDYRK1AF10WNT1
SCHEMBL2947646 0.92 SMN1; SMN2 (0.43) SMN1; SMN2GSK3BDYRK1AF10WNT1
SCHEMBL2946768 0.91 SMN1; SMN2 (0.45) SMN1; SMN2GSK3BDYRK1AF10WNT1
SCHEMBL2946774 0.91 SMN1; SMN2 (0.45) SMN1; SMN2GSK3BDYRK1AF10WNT1
SCHEMBL2947412 0.90 SMN1; SMN2 (0.42) SMN1; SMN2GSK3BDYRK1AF10WNT1
SCHEMBL13298962 0.90 SMN1; SMN2 (0.42) SMN1; SMN2GSK3BDYRK1AF10WNT1
SCHEMBL2945544 0.90 F10 (0.44) SMN1; SMN2GSK3BDYRK1AF10WNT1
SCHEMBL2947424 0.90 SMN1; SMN2 (0.42) SMN1; SMN2GSK3BDYRK1AF10WNT1
SCHEMBL2945536 0.90 F10 (0.44) SMN1; SMN2GSK3BDYRK1AF10WNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 SMN1; SMN2 4447/4885GSK3B 4638/4885DYRK1A 4229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback